FDA Extends Review of Praxis Epilepsy Drug Candidate Relutrigine by Three Months
As reported on BioSpace, Praxis Precision Medicines has received a three-month extension to the U.S. Food and Drug Administration’s review of relutrigine, its investigational therapy for rare genetic forms of…
Continue Reading
FDA Extends Review of Praxis Epilepsy Drug Candidate Relutrigine by Three Months
